Small-cell carcinoma

G1 Therapeutics Announces Upcoming Data at the American Society of Clinical Oncology (ASCO) Virtual 2021 Annual Meeting

Retrieved on:

Wednesday, May 19, 2021

Chemical compounds, Organic compounds, Protein kinase inhibitors, Breakthrough therapy, Piperazines, G1 Therapeutics, Antiestrogens, Selective estrogen receptor degrader, Trilaciclib, Palbociclib, Small-cell carcinoma

b'RESEARCH TRIANGLE PARK, N.C., May 19, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, today announced upcoming data presentations at the American Society of Clinical Oncology (ASCO) annual meeting, being held virtually June 4th through 8th.

Key Points:

b'RESEARCH TRIANGLE PARK, N.C., May 19, 2021 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, today announced upcoming data presentations at the American Society of Clinical Oncology (ASCO) annual meeting, being held virtually June 4th through 8th.
The presentations will describe results from the Company\xe2\x80\x99s study of its oral selective estrogen receptor degrader (SERD), rintodestrant, in combination with palbociclib for the treatment of ER+/HER2- advanced breast cancer as well as data describing the effects of COSELA\xe2\x84\xa2 (trilaciclib) on T-cell activation and clonal expansion in patients with newly diagnosed extensive-stage small cell lung cancer.
G1 has a deep clinical pipeline and is executing a tumor-agnostic development plan evaluating COSELA in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers.
G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics .\nG1 Therapeutics\xe2\x84\xa2 and the G1 Therapeutics logo and COSELA\xe2\x84\xa2 and the COSELA logo are trademarks of G1 Therapeutics, Inc.\n'

Pivotal Phase III Data at ASCO Show Genentech’s Tecentriq Helps Certain People With Early Lung Cancer Live Significantly Longer Without Their Disease Returning

Retrieved on:

Wednesday, May 19, 2021

In this population, Tecentriq increased DFS by a median of seven months (42.3 months vs. 35.3 months with BSC).

Key Points:

In this population, Tecentriq increased DFS by a median of seven months (42.3 months vs. 35.3 months with BSC).
Safety data for Tecentriq were consistent with its known safety profile and no new safety signals were identified.
It was the first approved cancer immunotherapy for front-line treatment of adults with extensive-stage small cell lung cancer in combination with carboplatin and etoposide (chemotherapy).
Tecentriq also has four approved indications in NSCLC as either a single agent or in combination with targeted therapies and/or chemotherapies.

Opdivo (nivolumab) Plus Yervoy (ipilimumab) with Two Cycles of Chemotherapy Demonstrates Durable Overall Survival vs. Chemotherapy at Two Years in First-Line Non-Small Cell Lung Cancer in Phase 3 CheckMate -9LA Trial

Retrieved on:

Wednesday, May 19, 2021

In the Phase 3 CheckMate -9LA trial, 38% of patients who received Opdivo plus Yervoy with two cycles of chemotherapy were alive at two years, compared to 26% of those who received chemotherapy alone.

Key Points:

In the Phase 3 CheckMate -9LA trial, 38% of patients who received Opdivo plus Yervoy with two cycles of chemotherapy were alive at two years, compared to 26% of those who received chemotherapy alone.
Non-small cell lung cancer (NSCLC) is one of the most common types of lung cancer, representing up to 84% of diagnoses.
Opdivo is currently approved in more than 65 countries, including the United States, the European Union, Japan and China.
In Checkmate 142 in MSI-H/dMMR mCRC patients receiving OPDIVO with YERVOY (n=119), serious adverse reactions occurred in 47% of patients.

Updated Amivantamab and Lazertinib Combination Data Demonstrate Durable Responses and Clinical Activity for Osimertinib-Relapsed Patients with EGFR-Mutated Non-Small Cell Lung Cancer

Retrieved on:

Wednesday, May 19, 2021

Lung cancer, Organic compounds, Chemical compounds, Branches of biology, Osimertinib, Non-small-cell lung carcinoma, Epidermal growth factor receptor, Biomarker, Small-cell carcinoma, T790M, RET inhibitor

"The results from this CHRYSALIS study cohort also offer promising insights that may help identify patients more likely to respond to an amivantamab and lazertinib combination regimen.

Key Points:

"The results from this CHRYSALIS study cohort also offer promising insights that may help identify patients more likely to respond to an amivantamab and lazertinib combination regimen.
Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response.
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (MARIPOSA).
EGFR Exon 20 Insertion Prognostic and Predictive Values in Advanced Non-Small Cell Lung Cancer, a Real World Study.

Amgen To Showcase New Data From Oncology Portfolio At ASCO 2021

Retrieved on:

Wednesday, May 19, 2021

Lung cancer, Cancer, Carcinoma, Cytopathology, Small-cell carcinoma, Clinical medicine, Medicine

"With new data from across our oncology portfolio, we are proud to drive the advancement of the potential next generation of targeted cancer treatments for patients who need it most.

Key Points:

"With new data from across our oncology portfolio, we are proud to drive the advancement of the potential next generation of targeted cancer treatments for patients who need it most.
"\nAdditional research to be presented at ASCO includes updated safety and efficacy data from the first-in-human (FIH) study of AMG 757 (tarlatamab) in small cell lung cancer (SCLC).
Administer corticosteroids for severe or life-threatening CRS.\nNeurological Toxicities: Approximately 65% of patients receiving BLINCYTOin clinical trials experienced neurological toxicities.
A breakdown, cyberattack or information security breach could compromise the confidentiality, integrity and availability of our systems and our data.

G1 Therapeutics Presents Two Posters at ISPOR Describing the Estimated Economic Impact of Treating Myelosuppression Among Patients with Extensive-Stage Small Cell Lung Cancer

Retrieved on:

Monday, May 17, 2021

Clinical medicine, Cancer, Medicine, Lung cancer, Oncology, Cancer treatments, Carcinoma, Cytopathology, Small-cell carcinoma, Trilaciclib, Bone marrow suppression, Chemotherapy

( poster )\nThe first poster details a cost-benefit model estimating the economic value from a U.S. commercial payer perspective of using COSELA\xe2\x84\xa2 (trilaciclib) prior to chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC).

Key Points:

( poster )\nThe first poster details a cost-benefit model estimating the economic value from a U.S. commercial payer perspective of using COSELA\xe2\x84\xa2 (trilaciclib) prior to chemotherapy in patients with extensive-stage small cell lung cancer (ES-SCLC).
( poster )\nThe second poster quantifies the impact of treatment-induced myelosuppression among Medicare patients diagnosed with SCLC, thereby contributing to the growing body of scientific evidence demonstrating the significant health burden, economic toll, and health-related quality-of-life effects of chemotherapy-induced myelosuppression.
\xe2\x80\x9cThese analyses add to the data that help clarify the potential positive financial impact of COSELA usage and the projected real-world economic value of COSELA.
SCLC, one of the two main types of lung cancer, accounts for about 10% to 15% of all lung cancers.

G1 Therapeutics Initiates Randomized Double Blind Placebo Controlled Phase 2 Study of COSELA™ (trilaciclib) in Non-Small Cell Lung Cancer (PRESERVE 4)

Retrieved on:

Monday, May 10, 2021

Lung cancer, Organic compounds, Chemical compounds, Breakthrough therapy, Chemistry, Piperazines, Cytopathology, Small-cell carcinoma, Trilaciclib, Non-small-cell lung carcinoma

We are exploring both potential benefits of COSELA in PRESERVE 4.\xe2\x80\x9d\nPatient enrollment in PRESERVE 4 is now underway.

Key Points:

We are exploring both potential benefits of COSELA in PRESERVE 4.\xe2\x80\x9d\nPatient enrollment in PRESERVE 4 is now underway.
The study will enroll approximately 146 patients, who will be randomly assigned (1:1) to receive COSELA or placebo prior to docetaxel on Day 1 of each 21-day cycle.
Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 84% of all lung cancer diagnoses.
This Phase 2 study may or may not replicate or further elucidate the survival benefit observed in our other COSELA trials.

IMFINZI and tremelimumab With Chemotherapy Demonstrated Overall Survival Benefit in POSEIDON Trial for 1st-line Stage IV Non-small Cell Lung Cancer

Retrieved on:

Friday, May 7, 2021

Oncology, Health, Clinical trials, General Health, Pharmaceutical, Biotechnology, Clinical medicine, Health, Cancer, Lung cancer, Breakthrough therapy, Orphan drugs, Monoclonal antibodies, Cancer treatments, Durvalumab, Tremelimumab, Non-small-cell lung carcinoma, Small-cell carcinoma

b"POSEIDON was a Phase III trial of AstraZeneca\xe2\x80\x99s IMFINZI\xc2\xae (durvalumab) plus platinum-based chemotherapy or IMFINZI, tremelimumab and chemotherapy versus chemotherapy alone in the 1st-line treatment of patients with Stage IV (metastatic) non-small cell lung cancer (NSCLC).\nPositive high-level results from the final analysis of POSEIDON showed the combination of IMFINZI, tremelimumab and chemotherapy demonstrated a statistically significant and clinically meaningful overall survival (OS) benefit versus chemotherapy alone.

Key Points:

b"POSEIDON was a Phase III trial of AstraZeneca\xe2\x80\x99s IMFINZI\xc2\xae (durvalumab) plus platinum-based chemotherapy or IMFINZI, tremelimumab and chemotherapy versus chemotherapy alone in the 1st-line treatment of patients with Stage IV (metastatic) non-small cell lung cancer (NSCLC).\nPositive high-level results from the final analysis of POSEIDON showed the combination of IMFINZI, tremelimumab and chemotherapy demonstrated a statistically significant and clinically meaningful overall survival (OS) benefit versus chemotherapy alone.
This immunotherapy combination also demonstrated a statistically significant improvement in progression-free survival (PFS) versus chemotherapy alone, as previously reported in October 2019 .
As both PFS endpoints were met for IMFINZI plus chemotherapy and IMFINZI, tremelimumab and chemotherapy, the prespecified statistical analysis plan allowed for independent OS testing for the IMFINZI plus tremelimumab and chemotherapy arm.
Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting.

Global Small Cell Lung Cancer Market to 2029 - Opportunity Analysis and Forecasts - ResearchAndMarkets.com

Retrieved on:

Tuesday, May 4, 2021

Pharmaceutical, Health, Oncology, Lung cancer, Health effects of tobacco, Cancer, Health, Small-cell carcinoma, Branches of biology

b'The "Small Cell Lung Cancer - Opportunity Analysis and Forecasts to 2029" report has been added to ResearchAndMarkets.com\'s offering.\nLung cancer remains a leading cause of cancer-related death worldwide and is a huge global health burden.

Key Points:

b'The "Small Cell Lung Cancer - Opportunity Analysis and Forecasts to 2029" report has been added to ResearchAndMarkets.com\'s offering.\nLung cancer remains a leading cause of cancer-related death worldwide and is a huge global health burden.
Small cell lung cancer constitutes approximately 10-15% of all lung cancers and is a subtype characterized by aggressive disease and a lack of therapeutic options, resulting in poor clinical outcomes for patients.
Despite the introduction of new market entrants, significant opportunity exists across several patient subsets and multiple lines of therapy for R&D.
the publisher anticipates 10 pipeline agents to be launched across the 8MM (the majority in China) over the forecast period 2019-2029.

Synthekine Appoints Internationally Recognized Cancer Immunotherapy Leader Naiyer Rizvi, M.D., as Chief Medical Officer

Retrieved on:

Monday, May 3, 2021

Oncology, Health, Genetics, Research, Science, Pharmaceutical, Biotechnology, Cancer treatments, Clinical medicine, Medicine, Cancer immunotherapy, Lung cancer, Antineoplastic drugs, Breakthrough therapy, Orphan drugs, Pembrolizumab, Immunotherapy, Small-cell carcinoma, Nivolumab

b'Synthekine Inc., an engineered cytokine therapeutics company, announced that it has appointed Naiyer Rizvi, M.D., as Chief Medical Officer, effective today.

Key Points:

b'Synthekine Inc., an engineered cytokine therapeutics company, announced that it has appointed Naiyer Rizvi, M.D., as Chief Medical Officer, effective today.
Dr. Rizvi is an internationally recognized leader in cancer immunotherapy drug development whose clinical research has helped deliver FDA approvals of several landmark immunotherapies, including nivolumab in squamous lung cancer and pembrolizumab in non-small cell lung cancer.
Rizvi most recently served as the Price Family Professor of Medicine, Director of Thoracic Oncology and Co-Director of Cancer Immunotherapy at Columbia University Medical Center.
Using the principles of cytokine partial agonism and immunological specificity, Synthekine designs differentiated therapeutics to be both safe and efficacious.